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Abstract
Biosimilar medicines have shown similarity with the originator biologic and offer a similar clinical outcome generally at a 
lower cost. This paper identifies benefits of off-patent biologics and biosimilars, and illustrates these benefits with empirical 
data from Europe. We provide a narrative review of published literature on values and benefits of biosimilars in Europe. The 
results describe cost savings as the key driver stemming from the lower price of biosimilars, than that of originator products, 
and from price competition between biosimilar(s), originator, and next-generation products. Cost savings may then translate 
into a number of other associated benefits. The lower price of biosimilars and similar effectiveness to the originator biolog-
ics improve cost effectiveness, implying that reimbursement can be granted or extended to other patient groups, or that the 
biologic therapy can be moved to an earlier line of treatment. Cost savings from biosimilars can be used to increase patient 
access to therapy or to increase the number of healthcare professionals. Finally, competition between off-patent biologics 
and biosimilars may stimulate an innovation in the formulation and development of next-generation biologics. Our paper 
illustrates that the benefit of off-patent biologics and biosimilars is not restricted to cost savings, but that these medicines 
may contribute to an expansion of medical treatment options for patients, hence concomitantly contributing to the long-term 
sustainability of the healthcare system. This review provides a broader view for clinical and economic decision makers and 
healthcare professionals on the added benefits of off-patent biologics and their use in clinical practice.
Key Points 
Biosimilars are generally cheaper than originator biolog-
ics and may also incite price reductions of originator bio-
logics; however, the benefit of biosimilars is not limited 
to cost savings.
Competition in European off-patent biologics and 
biosimilar markets may expand access to the treatment, 
improve cost effectiveness of the treatment, increase the 
number of healthcare professionals, and stimulate an 
incremental therapeutic innovation.
1 Introduction
Biologics are being used in the treatment of the most seri-
ous, life-threatening, and chronic diseases such as cancers 
[1], immune-mediated inflammatory conditions [2], diabetes 
mellitus [3], and fertility [4] and are likely to be of use in 
treating other diseases in the future. However, the clinical 
benefits of biologic therapy are offset by challenges related 
to affordability of and accessibility to biologic medicines 
[5].
Biosimilars are highly similar and clinically equivalent 
forms of originator biologics. Development of biosimi-
lars is complex because biologics are large and complex 
molecules derived from living cells by a complex manu-
facturing process. However, once assessed and licensed by 
an advanced regulatory agency, no meaningful difference 
between originator biologics and biosimilars is expected 
with respect to quality, safety and efficacy [5, 6]. Biosimi-
lars are marketed following expiration of patent and exclu-
sivities of the originator biologics. These medicines are 
generally less costly than the originator biologics, which 
may be due to an abbreviated clinical trial program, and 
 * Arnold G. Vulto 
 a.vulto@gmail.com
1 Department of Pharmaceutical and Pharmacological 
Sciences, KU Leuven, Louvain, Belgium
2 Hospital Pharmacy, Erasmus University Medical Center, 
Rotterdam, The Netherlands
 B. Dutta et al.
possibly also to a more advanced and efficient production 
process [7–10].
By 2018, 34 biologics have become off-patent and 15 
more biologics are expected to reach the patent cliff in the 
next 5 years in Europe [11, 12]. Hence, there is an oppor-
tunity for market access to biosimilars. As of May 2019, 
59 biosimilars have been approved in Europe, six authori-
zations have been withdrawn after approval, and there are 
six applications under evaluation for marketing approval 
[13]. These include growth factors (epoetins, filgrastim), 
hormones (follitropin-α, insulin glargine, somatropin, 
teriparatide), monoclonal antibodies and fusion proteins 
(adalimumab, infliximab, rituximab, etanercept), and low-
molecular weight heparins (enoxaparin sodium).
European countries have implemented a variety of 
incentives and policies to promote market access and 
uptake of biosimilars. The principle reason behind this 
favorable market environment is that countries wish to 
capture the savings arising from the lower price of bio-
similars in an era of restricted healthcare budgets, an 
increase in the burden of life-threatening diseases, early 
detection of these diseases, and an increase in the ageing 
population. Biosimilars are at least 15–45% less expensive 
than the originator biologics [14], although prices of bio-
similars vary across European countries [15]. However, 
price evolution of off-patent biologics and biosimilars is 
rapid across European countries and discounts on selected 
biosimilars can reach up to 80% [16]. Cumulative sav-
ings due to competition between originator biologics and 
biosimilars on eight key products (adalimumab, insulin 
glargine, etanercept, infliximab, rituximab, pegfilgrastim, 
trastuzumab, follitropin-α) are expected to reach €98 bil-
lion by 2020 in the EU group of 5 (G5: Germany, France, 
Italy, Spain, and UK) and the USA [17]. In Europe, the 
Top-10 biologics sales are €16.5 billion based on 2017 
sales figures [18]. Most of these biologics are off-patent 
in Europe and biosimilars to these biologics are available 
for clinical use. Assuming that the discount on off-patent 
biologics and biosimilars will be at least 50%, annual sav-
ings could be as large as €8–10 billion by 2020.
The key driver for uptake of biosimilars is cost reduction 
relative to the originator biologics; however, in this paper 
we argue that there are other associated benefits stemming 
from this key driver. Some of these value propositions of 
biosimilars have already been outlined in a recent opinion 
paper [19]; however, it did not describe all the benefits of 
biosimilars supported by empirical evidence. The aim of 
this study is to provide an in-depth and structured review of 
the key driver and associated benefits of off-patent biologics 
and biosimilars and to illustrate these benefits with empirical 
data from Europe. Based on these results, a broader view is 
presented to policy and decision makers, the pharmaceuti-
cal industry, and other stakeholders of different benefits of 
off-patent biologics and biosimilars, thereby supporting their 
optimal use in society.
2  Methods
A comprehensive literature search was performed for a nar-
rative review on the benefits of off-patent originator bio-
logics and biosimilars, and of competition in the off-patent 
biologics and biosimilars market. MEDLINE and EMBASE 
were searched for studies published between January 2005 
and November 2018, which encompassed the period during 
which biosimilars were first approved for use and launched 
in Europe [20]. Search terms were built on the concept of 
cost savings, economic evaluation, and other benefits of 
off-patent biologics and biosimilars beyond cost savings 
from payer, physician, patient, and market viewpoints. The 
search strings consisted of Medical Subject Heading (MeSH) 
and text terms for “biosimilar”, “reference, originator and 
off-patent medicines” and text terms for “value”, “lower 
price”, “price competition”, “supply chain benefit”, “access 
to treatment”, “competition”, “awarding reimbursement”, 
“extending reimbursement”, “earlier line of treatment”, 
“wrap around services”, “economic evaluation”, “off-patent 
biologics”, “cost effectiveness”, and “second generation ref-
erence product”. The PubMed MeSH terms were appropri-
ately modified in accordance with the EMBASE database. 
Given a paucity of published literature on benefits of off-
patent biologics and biosimilars as this is an emerging field 
of research, the bibliographic reference lists of eligible stud-
ies were also searched for other relevant sources such as the 
Generics and Biosimilar Initiative Journal (GaBI), which 
is not indexed in PubMed or EMBASE, and gray literature 
such as consultancy reports (IQVIA) and websites for the 
UK National Health Service (NHS), National Institute for 
Health and Care Excellence (NICE), and European Medi-
cines Agency (EMA). Articles were selected for inclusion if 
they reported empirical data on benefits in the off-patent bio-
logics and biosimilars markets in European countries. The 
search results from each database were limited to published 
references in the English language. Articles that reported 
on pharmaceutical or clinical aspects of off-patent biologics 
and biosimilars (such as bio-equivalence, immunogenicity, 
pharmacokinetics, or pharmacodynamic modelling) were 
excluded as such articles fell outside the scope of our lit-
erature review. A broad overview of the search strategy is 
schematically presented in Fig. 1.
3  Results
Figure 2 schematically presents different benefits of off-pat-
ent biologics and biosimilars for several stakeholders. This 
section defines and distinguishes between these benefits, 
Benefits of Off-Patent Biologics and Biosimilars in Europe
and includes an aggregate report on a number of empiri-
cal studies illustrating each benefit in the European setting. 
The price of biosimilars in these studies are the ex-manu-
facturing price or an average price weighted cost across EU 
G5 countries (France, Germany, Italy, Spain, and the UK). 
Results of empirical studies are outlined in Table 1. 
3.1  Cost Savings from Biosimilars
Cost savings may accrue from the lower price of biosimilars, 
than that of their originator products and from the price com-
petition between biosimilars, originator, and next-generation 
products. With respect to the former, our literature search 
identified eight empirical studies. Six of these studies carried 
out a hypothetical budget impact analysis of biosimilars and 
used it in a number of scenarios relating to the price differ-
ence between the originator product and biosimilars, and to 
other parameters such as uptake, conversion rate, and time 
horizon [21–26]. One study calculated actual savings arising 
from the introduction of biosimilar infliximab in a UK hos-
pital [26]. A Spanish study computed actual savings accru-
ing from competition between the reference, biosimilar, and 
new anti-tumor necrosis factor (TNF)-α products, and from 
therapeutic optimization [27]. All of these studies pointed to 
substantial savings in pharmaceutical costs, except for one 
study in which the budget increased when a new, alternative 
biologic entered the market during the time horizon of the 
budget impact analysis [28].
3.2  Improvement in Cost Effectiveness of Treatment
The lower price and similar effectiveness of biosimilars 
compared with the originator biologics improve the cost 
effectiveness of the biologic therapy [29–33], implying that 
reimbursement can be granted or extended to other patient 
groups.
Improved cost effectiveness of biosimilars may also allow 
biologic therapy to be used in an earlier line of treatment 
STRATEGY                                                 NUMBER OF PUBLICATIONS SELECTED
European studies
(empirical evidence)
Additional 65 articles (n=180)
Names of all off-patent biologics and biosimilars approved in 
Europe* (n=1175)
Reports: IQVIA, Deloitte 
Guidelines: EMA/NICE
Journals not indexed in 
PubMed (GaBI)
Names of biologics and
biosimilars (EMA list)*
Search terms on Biologics & 
Biosimilars
All articles on “Biologics & Biosimilars” on PubMed (n= 8360)
Human studies on Biologics & Biosimilars 
Time horizon: Jan 2005 till Nov 2018 (n=4286)
Search terms in title or 
abstract for “benefits” such as 
“cost savings”, “saving”,
"economic evaluation”, etc.**
Selected (empirical studies in Europe) for a narrative review on 
benefits of off-patent biologics and biosimilars
(n=46)
Human studies
Benefits of off-patent biologics and biosimilars (n=461)
Selected articles based on title and abstract (n=115)
Excluded articles because 
outside scope of study (n=134) 
Fig. 1  A broad search strategy and different stages of narrative literature search. *IQVIA Report [20]; **see Sect. 2. EMA European Medicines 
Agency, GaBI Generics and Biosimilar Initiative Journal, NICE National Institute for Health and Care Excellence
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and enable patients to access the biologic therapy at an early 
stage of disease. For instance, biosimilar filgrastim was 
moved to first-line cancer treatment in the UK as a result of 
its improved cost effectiveness when compared to alternative 
treatments [34]. This suggests that the cost effectiveness of 
originator biologics should be re-visited with new cost data 
on biosimilars.
3.3  Increase in Patient Access to Pharmacological 
Treatment
Cost savings from biosimilars can be used to increase patient 
access to biologic therapy. Several hypothetical budget 
impact studies have computed how many additional patients 
with the same disease or how many patients with a different 
disease can be treated with the money saved from biosimilars 
[22, 24]. A Swedish study showed that there was an increase 
in patient access to filgrastim treatment when restrictions to 
prescribe filgrastim for febrile neutropenia were relaxed fol-
lowing the market entry of biosimilar filgrastim in a specific 
region [17, 35].
Cost savings from biosimilars may also serve to support 
patient access to other innovative treatments. Two simulation 
studies showed how access to targeted antineoplastic treat-
ments could be expanded by drawing on savings generated 
by treating chemotherapy-induced febrile neutropenia with 
biosimilar filgrastim and by treating anemia with biosimilar 
epoetin alfa [21, 25].
3.4  Increase in the Number of Healthcare 
Professionals
Cost savings from biosimilars can be divided among stake-
holders (such as payers, hospitals, and physicians) through 
so-called ‘gain-sharing arrangements’ with a view to pro-
moting uptake of biosimilars [36], and could be reinvested 
in employing a greater number of healthcare professionals. 
This efficient reallocation of savings can reduce the wait-
ing time for patients and improve utilization of healthcare 
resources in a capacity-constrained hospital [26, 37].
3.5  Incremental Innovation of Biologics
Competition between off-patent biologics and biosimi-
lars may stimulate innovations in formulation, route of 
administration (e.g., intravenous vs. subcutaneous), new 
approaches to promote patient adherence to the treatment, 
and development of next-generation biologics (e.g., fil-
grastim, pegfilgrastim, and lipegfilgrastim). There are both 
tangible and intangible benefits from innovation in the for-
mulation, which could be extended to patient flexibility, 
patient care, and productivity, hence resulting in an overall 
societal gain [38, 39]. However, reimbursement of incre-
mental innovation varies across European countries, which 
might be detrimental relating to the uptake of improved 
off-patent biologics [39]. Moreover, incremental innova-
tion of the originator biologic compared with the biosimi-
lar may be expensive; hence, such innovations warrant an 
economic evaluation to demonstrate their cost effective-
ness. These features may not be clinically superior or cost 
effective, and therefore it may not be a preferred choice for 
physicians to treat their patients at a higher cost [40, 41].
4  Discussion
Although the impetus for biosimilars development has 
been largely a reduction in the cost of biologics, there 
are other benefits emerging from the main argument of 
cost saving, which have been illustrated in this narrative 
review and supported by empirical data within Europe 
such as cost savings related to the use of biosimilars could 
be reallocated to increase access to biologic therapy for 
Off-patent originator 
biologic
Biosimilar Innovator biologic
Price competition
New formulation
New administration route
Next generation biologics
Cost savings from off-patent and BioS competition
Physicians ProviderPayerPatients
• Treatment options of biologic vs 
conventional therapy (increase cost- 
effectivenesss of BioS)
• Wider treatment options within a 
therapeutic class
• Autonomy to prescribe BioS
• Increase patient access to the same biologic 
treatment
• Patient access to innovative therapies
• Improve patient access/ease of 
use/adherence by use of next generation 
biologics 
• Moving therapy to an earlier line of therapy 
(improve cost-effectiveness of BioS)
• Include reimbursement of BioS in new 
indications 
• Improve healthcare process and 
infrastructure 
• Increase in number of healthcare providers
• Add-on service for patient care
Fig. 2  Benefits of off-patent biologics and biosimilars for different stakeholders. BioS biosimilars
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patients who could not previously be treated, the biologic 
therapy could be moved to an earlier line of treatment, 
demand would be reallocated within a broader class of 
medicines, and there could be an increase in the number of 
healthcare staff. The benefits arising from the cost contain-
ment have different impacts on various healthcare stake-
holders and are schematically represented in Fig. 2. These 
benefits are inter-related; for example, improving the cost 
effectiveness of the biotherapeutic treatment may move 
therapy to an earlier line of treatment, widening patient 
access and thus resulting in a better health outcome for 
more patients. Cost savings by the use of lower-priced 
off-patent biologics and biosimilars could be reallocated to 
increase patient access to innovative therapies, thus foster-
ing headroom for innovations and supporting holistic ben-
efit of biotherapeutics. Hence, benefits associated with the 
use of off-patent medicines and biosimilars are integrated 
and not additive.
Competition between off-patent biologics and biosimi-
lars stimulates incremental innovation by pharmaceutical 
companies. However, incremental innovation by the origi-
nator manufacturing company could also be related to a 
strategic pricing policy put in place by the manufacturing 
company for the originator medicine before the launch of 
biosimilars, and developing next-generation products with 
better formulations and other add-on features could be a 
defense mechanism to save the market share of the origi-
nator medicines. These innovations may not be clinically 
superior to the biosimilar or originator [40].
Our study has illustrated the key benefits in the Euro-
pean off-patent biologics and biosimilars market with 
practical examples as derived from budget impact analy-
ses, economic evaluations, and other studies. The short-
comings of these studies, such as a limited range of cost 
parameters, assumptions used to populate the budget 
impact model regarding hypothetical drug pricing and bio-
similars uptake, the limited range of sensitivity analysis, 
lack of local adaptation and validation of economic stud-
ies, have been analyzed in the literature [5] and fell outside 
the scope of this study. The value of biosimilars may also 
be different across various regions of Europe. For Central 
and Eastern European countries, access to the originator 
biologics and biosimilars is a major challenge, whereas in 
Western European countries, the high price of these medi-
cines is a major issue, which poses a financial burden to 
the healthcare system. Empirical studies illustrating ben-
efits of biosimilars (Table 1) are based on hypothetical or 
descriptive studies from one or a few countries. The results 
cannot be generalized on the same parameters across all 
European countries.
The reimbursement system is different in each country 
and patients’ access to the biologic treatments may still be 
challenging, especially if there is a co-payment or limited 
insurance coverage for these novel therapies. As a result, 
patients are less likely to have access to these expensive 
biologic treatments [43, 44]. The purchasing price of off-
patent originators and biosimilars, which is regulated by 
the national authority, can also vary in different European 
countries, and within the same country prices may also be 
different if dispensed via ambulatory care or a retailer [15]. 
Additionally, there could be other factors such as a negoti-
ated price between the manufacturers and hospitals, local 
tenders, existing contractual arrangements, and the price 
sensitivity of payers for biosimilars. Sometimes the price 
of the off-patent originator may also be lower  than that 
of biosimilars. Moreover, healthcare resources in Central 
and Eastern European countries are lower than in Western 
European countries [44]. An increase in patient access to 
pharmacological treatment is, therefore, likely to be a more 
relevant benefit in Central and Eastern European countries, 
where equity of access to the treatment is more of an issue 
than in other European countries. The current body of evi-
dence illustrated in Table 1 is derived from hypothetical 
and descriptive studies in specific countries, thus inhibiting 
the generalizability of results. Due to the heterogeneity of 
the reimbursement systems and biosimilar policies between 
countries, benefits of off-patent biologics and biosimilars 
markets observed in one country cannot be extrapolated to 
another country. Therefore, there is a need to investigate 
and conduct a comparative analysis of benefits in off-patent 
originator biologics and biosimilars markets at a national, 
regional, and local level. Reimbursement assistance and 
innovative financial agreements may add to the overall ben-
efits of the biologic therapy. Additionally, access to these 
biologic medicines can be improved by including them in the 
list of World Health Organization (WHO) essential medi-
cines, based on their cost and clinical effectiveness data. 
This could be a supportive argument for off-patent origina-
tor biologics and biosimilars being included in the national 
reimbursement lists of many countries. Furthermore, in an 
integrated health system, gain-sharing arrangements may be 
a potential solution to distributing cost savings from bio-
similars, such as increasing the number of specialized nurses 
and support staff for a high-quality, cost-effective patient 
service, resulting in a favorable patient outcome [37]. These 
initiatives could also promote team-based approaches for a 
continuous process improvement in hospital settings.
Our literature search included benefits of the off-patent 
originator biologics and biosimilars market for which Euro-
pean empirical data were available. Although additional 
drivers such as innovation in manufacturing technology, 
new branding, and marketing strategies exist, we did not find 
publicly available empirical data supporting these benefits.
Although our study has focused on those factors that 
contribute to the benefit of competition in the off-patent 
biologics and biosimilars markets, other factors exist that 
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undermine the attainment of benefits in this market. For 
instance, there has been a low uptake of biosimilars due 
to lack of confidence among physicians prescribing these 
medicines [45] and a ‘nocebo’ effect experienced by patients 
when switching originator medicines to biosimilars [46] 
in which patients anticipate negative consequences after 
switching to biosimilars from the originator biologic, which 
may lead to a negative implication on their health outcome. 
These barriers can be addressed by providing professional 
education with scientific evidence to prescribers, and imple-
menting an awareness program regarding the use and poten-
tial benefits of biosimilars for patients and other healthcare 
professionals.
Future studies are required to analyze and illustrate other 
benefits of competition in the off-patent biologics and bio-
similars markets, such as a robust supply chain to avoid drug 
shortages, professional education for healthcare profession-
als, and patient care pathways. Also, empirical research 
illustrating the various benefits of off-patent biologic medi-
cines and biosimilars needs to move away from hypothetical 
studies to evidence generated from real-world data.
5  Conclusion
In this article we have reviewed benefits offered by off-patent 
biologic medicines and biosimilars, beyond cost contain-
ment. These benefits may include improving patient access 
and affordability, moving biologic treatment to an earlier line 
of therapy, and provision of budget flexibility to fund novel 
therapies. Off-patent biologics and biosimilars may also cre-
ate market competition and stimulate incremental innova-
tion by the manufacturers. These benefits when executed 
in real-life scenarios could result in wider use of biologic 
treatments than the standard of care in inflammatory dis-
eases and oncology.
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